Abstract
Lamprey gonadotropin-releasing hormone-III (lGnRH-III; Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2), a native isoform of human GnRH (GnRH-I), was initially isolated from the brain of the sea lamprey (Petromyzon marinus). It is a weak GnRH agonist, which exerts a direct antiproliferative effect on cancer cells and has an insignificant LH and FSH releasing potency in mammals. These features reveal the advantages of lGnRH-III and its derivatives for use in cancer therapy. Here we give an overview of various strategies to increase the antitumor activity of lGnRH-III, such as amino acid replacement, cyclization, dimerization and conjugation to polymers or to chemotherapeutic agents. In vitro and in vivo antitumor activity of lGnRH-III based compounds was demonstrated both on hormone dependent and independent tumors.
Keywords: Lamprey gonadotropin-releasing hormone-III (lGnRH-III), anticancer activity, targeted cancer chemotherapy, anthracyclines, peptide dimers, drug - peptide conjugates, antiproliferative effect, chemotherapeutic agent, tumor, steroid
Protein & Peptide Letters
Title:lGnRH-III - a Promising Candidate for Anticancer Drug Development
Volume: 20 Issue: 4
Author(s): Marilena Manea and Gabor Mezo
Affiliation:
Keywords: Lamprey gonadotropin-releasing hormone-III (lGnRH-III), anticancer activity, targeted cancer chemotherapy, anthracyclines, peptide dimers, drug - peptide conjugates, antiproliferative effect, chemotherapeutic agent, tumor, steroid
Abstract: Lamprey gonadotropin-releasing hormone-III (lGnRH-III; Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2), a native isoform of human GnRH (GnRH-I), was initially isolated from the brain of the sea lamprey (Petromyzon marinus). It is a weak GnRH agonist, which exerts a direct antiproliferative effect on cancer cells and has an insignificant LH and FSH releasing potency in mammals. These features reveal the advantages of lGnRH-III and its derivatives for use in cancer therapy. Here we give an overview of various strategies to increase the antitumor activity of lGnRH-III, such as amino acid replacement, cyclization, dimerization and conjugation to polymers or to chemotherapeutic agents. In vitro and in vivo antitumor activity of lGnRH-III based compounds was demonstrated both on hormone dependent and independent tumors.
Export Options
About this article
Cite this article as:
Manea Marilena and Mezo Gabor, lGnRH-III - a Promising Candidate for Anticancer Drug Development, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040008
DOI https://dx.doi.org/10.2174/0929866511320040008 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The ACE Insertion/Deletion Polymorphism and Risk of Cancer, a Review and Meta-Analysis of the Literature
Current Cancer Drug Targets Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Development of Anti-HIV Agents Targeting Dynamic Supramolecular Mechanism: Entry and Fusion Inhibitors Based on CXCR4/CCR5 Antagonists and gp41-C34-Remodeling Peptides
Current HIV Research The Skeletal Effects of Gonadotropin-Releasing Hormone Antagonists: A Concise Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry The New Perspectives on Genetic Studies of Type 2 Diabetes and Thyroid Diseases
Current Genomics An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry Prostate Cancer with Variants in CYP17 and UGT2B17 Genes: A Meta-Analysis
Protein & Peptide Letters 5-Lipoxygenase: A Promising Drug Target Against Inflammatory Diseases-Biochemical and Pharmacological Regulation
Current Drug Targets Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry A Functional Proteomic Approach to the Identification and Characterization of Protein Composition in Wheat Leaf
Current Proteomics Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Synthesis and Anti-cancer Activity of 3-substituted Benzoyl-4-substituted Phenyl-1H-pyrrole Derivatives
Anti-Cancer Agents in Medicinal Chemistry Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Design, Synthesis and Biological Evaluation of Novel 1, 3- thiazolidine-2, 4-diones as Anti-prostate Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hydrogen Sulphide and Pain
Inflammation & Allergy - Drug Targets (Discontinued)